Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Salient Surgical eyes $86m with IPO

This article was originally published in Clinica

Executive Summary

Salient Surgical Technologies, the surgical products specialist formerly known as TissueLink Medical, is aiming to raise $86m through an IPO on the Nasdaq Stock Exchange. The Dover, New Hampshire-based company said that it will use the proceeds from the offering to fund expansion in sales and marketing, develop new products and repay outstanding debt. Salient Surgical is currently developing the Aquamantys system, which is designed to seal blood vessels in soft tissue and bone, in order to reduce blood loss during surgery and lower the risks associated with blood transfusion. The company is focused on orthopaedic hip and knee reconstruction procedures (of which there were 1.2 million in 2007 in the US alone, according to Medtech Insight), as well as multi-level spinal fusions (a further 135,000 procedures). The company will trade under the ticker symbol "SLNT".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel